Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication

AIDS

Volumn 14, Issue 11, 2000, Pages 1481-1488

  Ioannidis, John P A ^a,b   Havlir, Diane V ^d   Tebas, Pablo ^g   Hirsch, Martin S ^c   Collier, Ann C ^h   Richman, Douglas D ^d,e,f  

^a UNIVERSITY OF IOANNINA   (Greece)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; HIV 1; Mathematical modeling; Viral fitness; Viral load; Viral rebound

Indexed keywords

INDINAVIR; LAMIVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAINTENANCE THERAPY; MALE; MATHEMATICAL MODEL; PRIORITY JOURNAL; REBOUND; TREATMENT OUTCOME; VIREMIA; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; LAMIVUDINE; MALE; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VIRAL LOAD; VIRUS REPLICATION; ZIDOVUDINE;

EID: 0033816087     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200007280-00003     Document Type: Article

References (27)

1. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management
2. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at its nadir
3. Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment
4. High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy
5. Rebound of plasma HIV viral load following prolonged suppression with combination therapy
6. Rebound of HIV-1 viral load after suppression to very low levels
7. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral replication
8. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinstated treatment
9. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy
10. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy
11. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
12. Quantitative image analysis of HIV-1 infection in lymphoid tissue
13. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life span, and viral generation time
14. Alternative splice acceptor utilization during human immunodeficiency virus type 1 infection of cultured cells
15. Viral dynamics of acute HIV-1 infection
16. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy
17. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro
18. Human immunodeficiency virus fitness in vivo: Calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase
19. Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase
20. Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads
21. In vivo HIV-1 replicative capacity in early and advanced infection